UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/17.12.25 | Real-time Bid/Ask 05:38:56 2024-07-05 EDT | ||
| 6.14 EUR / 6.28 EUR | +1.64% |
|
| Current month | -1.61% | ||
| 1 month | -2.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 6.04 | -1.15% |
| 24-07-04 | 6.11 | -2.86% |
| 24-07-03 | 6.29 | +2.61% |
| 24-07-02 | 6.13 | -2.70% |
| 24-07-01 | 6.3 | +1.45% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 02:24 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1H5B |
| ISIN | DE000HD1H5B2 |
| Date issued | 2023-12-28 |
| Strike | 500 $ |
| Maturity | 2025-12-17 (531 Days) |
| Parity | 10 : 1 |
| Emission price | 9.61 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.83 € |
|---|---|
| Lowest since issue | 5.79 € |
| Spread | 0.14 € |
| Spread % | 2.24% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
